Laurent Chardonnet's most recent trade in Prelude Therapeutics Inc was a trade of 150,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 1, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.50 per share. | 23 May 2023 | 5,000 | 42,165 | - | 5.5 | 27,500 | Common Stock |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 135,000 | 135,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2022 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.76 per share. | 08 Dec 2022 | 10,000 | 35,873 | - | 4.8 | 47,600 | Common Stock |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.23 per share. | 01 Jun 2022 | 10,000 | 24,500 | - | 4.2 | 42,300 | Common Stock |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 7.51 per share. | 21 Mar 2022 | 6,500 | 14,500 | - | 7.5 | 48,815 | Common Stock |
| Prelude Therapeutics Inc | Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) |